ESSA Pharma
EPIX
EPIX was delisted on the 8th of October, 2025.
59 hedge funds and large institutions have $119M invested in ESSA Pharma in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 21 reducing their positions, and 19 closing their positions.
1.23% more ownership
Funds ownership: 84.5% → 85.73% (+1.2%)
16% less funds holding
Funds holding: 70 → 59 (-11)
48% less capital invested
Capital invested by funds: $230M → $119M (-$111M)
52% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 21
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$11.8M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.37M |
| 3 |
JP Morgan Chase
New York
|
+$1.13M |
| 4 |
Millennium Management
New York
|
+$697K |
| 5 |
HF
HRT Financial
New York
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.5M |
| 2 |
Janus Henderson Group
London,
|
-$3.15M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.79M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.32M |
| 5 |
BlackRock
New York
|
-$525K |
EPIX Hedge Fund Activity: Q2 2022 in Review
59 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q2 2022, worth a combined $119M — down 48% from $230M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of EPIX and 8 opened new positions — a net loss of 11 holders — while 21 trimmed existing stakes and 10 added.
The largest buyer was Morgan Stanley, adding an estimated $11.8M. The largest seller was Eventide Asset Management, cutting an estimated $4.5M.
- 59 institutional investors held ESSA Pharma (EPIX) as of Q2 2022, down from 70 in Q1 2022.
- Funds reported $119M of ESSA Pharma stock for Q2 2022, down 48% quarter-over-quarter.
- 8 funds opened new ESSA Pharma positions in Q2 2022 and 19 closed out, a net change of -11 holders.
- The largest ESSA Pharma buyer in Q2 2022 was Morgan Stanley, an estimated $11.8M added.
- The largest ESSA Pharma seller in Q2 2022 was Eventide Asset Management, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2022.